Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial

Trial Profile

Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Colesevelam (Primary) ; Ezetimibe
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GOAL-RCT
  • Most Recent Events

    • 15 Nov 2017 Status changed from recruiting to active, no longer recruiting according to results presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Primary endpoint of proportion of subjects who achieve target HbA1c and LDL cholesterol has been met, according to results presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top